Cargando…

PB2358: PHASE 1-2 STUDY OF THE SAFETY, PK, PD, AND PRELIMINARY ACTIVITY OF TOLINAPANT IN COMBINATION WITH ORAL DECITABINE/CEDAZURIDINE AND ORAL DECITABINE/CEDAZURIDINE ALONE IN SUBJECTS WITH R/R PTCL

Detalles Bibliográficos
Autores principales:	Shortt, Jake, Poligone, Brian, Ribrag, Vincent, Zinzani, Pier Luigi, El-Sharkawi, Dima, Walewski, Jan, Prica, Anca, Wilson, Laksmi, Souza, Sonia, Keer, Harold, Taylor, Jason, Marchi, Enrica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429443/ http://dx.doi.org/10.1097/01.HS9.0000976148.07947.e7

Ejemplares similares

Decitabine/Cedazuridine: First Approval
por: Dhillon, Sohita
Publicado: (2021)

Correction to: Decitabine/Cedazuridine: First Approval
por: Dhillon, Sohita
Publicado: (2020)

Decitabine/cedazuridine for chronic myelomonocytic leukaemia, myelodysplastic syndromes
Publicado: (2022)

The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia
por: Briski, Robert, et al.
Publicado: (2023)

P741: PATIENTS’ PERSPECTIVES ON ORAL DECITABINE AND CEDAZURIDINE FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
por: Zeidan, Amer M., et al.
Publicado: (2023)

Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada
por: Yun, John Paul, et al.
Publicado: (2023)

Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain Phase 3 Study
por: Savona, Michael R., et al.
Publicado: (2021)

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Savona, Michael R., et al.
Publicado: (2020)

Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study
por: Garcia-Manero, Guillermo, et al.
Publicado: (2021)

PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)
por: Zeidan, Amer M., et al.
Publicado: (2023)

Reversible cardiomyopathy in a patient with chronic myelomonocytic leukemia treated with decitabine/cedazuridine: a case report
por: Sheel, Ankur, et al.
Publicado: (2023)

P735: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES
por: Robert Savona, Michael, et al.
Publicado: (2023)

Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model
por: Ramsey, Haley E., et al.
Publicado: (2020)

S172: PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
por: Bataller, Alex, et al.
Publicado: (2023)

P719: RANDOMIZED PHASE 1-2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS
por: Garcia-Manero, Guillermo, et al.
Publicado: (2023)

P1142: AFM13 IN PATIENTS WITH R/R PERIPHERAL T CELL LYMPHOMA (PTCL): A POST-HOC SUBGROUP ANALYSIS FROM THE REDIRECT STUDY
por: Kim, Won-Seog, et al.
Publicado: (2023)

Di-O-lauroyl-decitabine-lipid nanocapsules: toward extending decitabine activity
por: Briot, Thomas, et al.
Publicado: (2019)

Decitabine in the treatment of myelodysplastic syndromes
por: Saba, Hussain I
Publicado: (2007)

5613127 PHARMACOKINETICS AND PHARMACODYNAMICS OF AN INNOVATIVE ORAL FORMULATION OF DECITABINE AND TETRAHYDROURIDINE IN HEALTHY PEOPLE
por: Saunthararajah, Y., et al.
Publicado: (2023)

Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome
por: Qin, Taichun, et al.
Publicado: (2011)

Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis
por: Kwag, Daehun, et al.
Publicado: (2022)

Mixed-phenotype acute leukemia treated with decitabine
por: Lee, Ji-Young, et al.
Publicado: (2016)

Epigenetic synergy between decitabine and platinum derivatives
por: Qin, Taichun, et al.
Publicado: (2015)

Spotlight on decitabine for myelodysplastic syndromes in Chinese patients
por: Jing, Yu, et al.
Publicado: (2015)

Decitabine Induced Delayed Cardiomyopathy in Hematologic Malignancy
por: Agasthi, Pradyumna, et al.
Publicado: (2018)

Expression of decitabine-targeted oncogenes in meningiomas in vivo
por: Canisius, Julian, et al.
Publicado: (2022)

Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine
por: HOSOKAWA, MIKA, et al.
Publicado: (2015)

Decitabine Induced Transient Cardiomyopathy: A Case Report
por: De, Chitradeep, et al.
Publicado: (2012)

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes
por: Garcia, Jacqueline S, et al.
Publicado: (2010)

Decitabine reactivated pathways in platinum resistant ovarian cancer
por: Fang, Fang, et al.
Publicado: (2014)

Decitabine in the treatment of acute myeloid leukemia in elderly patients
por: Malik, Priya, et al.
Publicado: (2014)

Direct but No Transgenerational Effects of Decitabine and Vorinostat on Male Fertility
por: Kläver, Ruth, et al.
Publicado: (2015)

Effects of decitabine on megakaryocyte maturation in patients with myelodysplastic syndromes
por: DING, KAI, et al.
Publicado: (2016)

Decitabine: a historical review of the development of an epigenetic drug
por: de Vos, Dick, et al.
Publicado: (2005)

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
por: Goswami, Meghali, et al.
Publicado: (2022)

Selinexor in Combination with Decitabine Attenuates Ovarian Cancer in Mice
por: Stiff, Patrick J., et al.
Publicado: (2023)

Establishment and molecular characterization of decitabine‐resistant K562 cells
por: Wen, Xiang‐Mei, et al.
Publicado: (2019)

Novel prodrugs of decitabine with greater metabolic stability and less toxicity
por: Hattori, Naoko, et al.
Publicado: (2019)

Therapeutic effect of TRC105 and decitabine combination in AML xenografts
por: Baik, June, et al.
Publicado: (2020)

Clinical effect of decitabine in the treatment of myelodysplastic syndrome and influencing factors
por: Liu, Tangxia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_746bcd43o7b32qqvf8nhu142ol